5 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Suspended 1 |
| Phase 2 | 2 | Completed 2 |
Follow Cutaneous T Cell Lymphoma: new trials by email Literature Review of Cutaneous T Cell Lymphoma trials Research Report on Cutaneous T Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) Ropeginterferon alfa-2b - Cutaneous T Cell Lymphoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 38 | 2025-08-27 | 2026-04-01 |
| A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System BITR2101 - NHL, Cutaneous T Cell Lymphoma | Phase 1 | Not yet recruiting | Boston Immune Technologies and Therapeutics | 37 | 2025-08-01 | 2025-07-08 |
| Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Suspended | University of Alabama at Birmingham | 10 | 2023-05-01 | 2026-06-15 |
| A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors SIM1811-03 or in combination with Sintilimab injectiont - Advanced Solid Tumor, Cutaneous T Cell Lymphoma | Phase 1 | Unknown | Jiangsu Simcere Biologics Co., Ltd | 255 | 2022-03-06 | 2023-09-21 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat [14C]-resminostat - Cutaneous T Cell Lymphoma, Mycosis Fungoides | Phase 1 | Completed | 4SC AG | 5 | 2021-10-12 | 2022-02-18 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer GZ17-6.02, Capecitabine - Advanced Cancer, Gastric Cancer | Phase 1 | Unknown | Genzada Pharmaceuticals USA, Inc. | 127 | 2019-03-01 | 2022-12-23 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases | Phase 1 | Active not recruiting | UNC Lineberger Comprehensive Cancer Center | 43 | 2018-10-29 | 2026-06-12 |
| Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies Tinostamustine - Hematological Malignancies, Multiple Myeloma | Phase 1 | Completed | Mundipharma Research Limited | 106 | 2016-04-14 | 2024-07-25 |
| Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) Micro needle array-Doxorubicin (MNA-D) - Cutaneous T Cell Lymphoma | Phase 1 | Completed | Falo, Louis, MD | 20 | 2016-03-09 | 2024-08-09 |
| Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) Topical resiquimod 0.06%, topical resiquimod 0.03% - Cutaneous T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 13 | 2012-02-01 | 2019-08-13 |
| RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative | Phase 1 / Phase 2 | Completed | Samsung Medical Center | 46 | 2010-07-01 | 2015-03-03 |
Lymphoma, T-Cell, Cutaneous (11) · Mycosis Fungoides (4) · Lymphoma (2) · Sezary Syndrome (2) · Breast Neoplasms (1) · Carcinoma, Basal Cell (1) · Colonic Neoplasms (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Immune System Diseases (1) · Immunoblastic Lymphadenopathy (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (11) · Lymphoma, Non-Hodgkin (11) · Neoplasms by Histologic Type (11) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoma, T-Cell (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Lymphoma (9) · Neoplasms by Site (2) · Blood Protein Disorders (1) · Breast Diseases (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1)
Doxorubicin (2) · Bendamustine Hydrochloride (1) · Brentuximab Vedotin (1) · Capecitabine (1) · Cyclophosphamide (1) · Everolimus (1) · Prednisolone (1) · Transdermal Patch (1) · Vincristine (1) · fludarabine (1) · mogamulizumab (1) · tinostamustine (1)
4SC AG (1) · Abramson Cancer Center at Penn Medicine (1) · Boston Immune Technologies and Therapeutics (1) · Falo, Louis, MD (1) · Genzada Pharmaceuticals USA, Inc. (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Jiangsu Simcere Biologics Co., Ltd (1) · Mundipharma Research Limited (1) · Samsung Medical Center (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of Alabama at Birmingham (1)
United States (7) · China (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Alain H Rook, M.D. (1) · Kathryn Gazarik (1) · Lauren Shea, M.D. (1) · Natalie Grover, MD (1) · Oleg E Akilov, MD, PhD (1) · Pier L Zinzani, MD,PhD (1) · Ruihua Xu, MD (1) · Won Seog Kim, MD, PhD (1) · Yumeng Zhang, MD (1)
PMID 26228486, PMID 35276694, PMID 37589506, PMID 38758815, PMID 39617826, PMID 39821757
R01CA247497 (1)